NICE Approves Alnylam's Vutrisiran for NHS Use in Rare Heart Condition ATTR-CM
核心洞察
NICE has approved vutrisiran (Amvuttra) for NHS use in England and Wales, providing a new treatment option for approximately 1,500 patients with transthyretin amyloidosis with cardiomyopathy (搜索) (ATTR-CM (搜索)).
The drug is administered as a subcutaneous injection every three months at home, offering an alternative to the daily oral medication tafamidis already available on the NHS.
Clinical evidence suggests vutrisiran provides similar effectiveness to tafamidis in extending life and delaying disease progression, with comparable or lower costs.
The National Institute for Health and Care Excellence (NICE) has approved vutrisiran for NHS use in England and Wales, marking a significant advancement in treating transthyretin amyloidosis with cardiomyopathy (搜索) (ATTR-CM (搜索)), a rare and progressive heart condition affecting approximately 1,500 individuals in these regions.
New Treatment Option for Devastating Heart Condition
Vutrisiran, marketed as Amvuttra by Alnylam Pharmaceuticals (搜索), offers patients a novel therapeutic approach for ATTR-CM (搜索), a debilitating condition where the liver-produced protein transthyretin (搜索) misfolds, creating deposits that stiffen the heart. Patients typically experience symptoms including shortness of breath, chest pain, and swelling in the lower legs, with the progressive condition potentially leading to heart failure (搜索) without intervention.
The drug works by binding to and silencing messenger RNA (mRNA (搜索)) to reduce the amount of transthyretin (搜索) produced by the liver. This mechanism represents a gene-silencing approach that addresses the root cause of protein misfolding in ATTR-CM (搜索).
Convenient Administration and Clinical Efficacy
The treatment is administered as a subcutaneous injection every three months, which patients can receive at home, offering significant convenience compared to existing therapies. This dosing regimen represents an improvement over Alnylam's earlier ATTR amyloidosis therapy Onpattro (patisiran), which requires intravenous administration every few weeks.
According to NICE's assessment, evidence suggests vutrisiran helps people live for about as long as those receiving tafamidis, the first treatment for ATTR-CM (搜索) approved for NHS use in 2024. The guidance indicates that vutrisiran delays disease progression at a similar rate to tafamidis, with costs that are similar to or lower than the existing treatment.
Strong Clinical Trial Results
Recent data from the phase 3 HELIOS-B trial demonstrated vutrisiran's clinical benefit, showing the drug reduced the risk of the composite of all-cause mortality or first cardiovascular event by up to 42% compared to placebo over four years. This data supports the drug's efficacy in managing this life-threatening condition.
Healthcare Professional and Patient Advocacy Response
Anna Tomlinson, chief executive of Cardiomyopathy UK, emphasized the significance of this approval: "ATTR-CM (搜索) is a devastating, progressive condition that often goes undiagnosed for months, or even years. It may not only lead to heart failure (搜索), but also seriously impact a person's daily life. New treatment options are therefore vitally important, and we welcome Nice's decision to make vutrisiran available on the NHS across England and Wales."
Professor Bryan Williams, chief scientific and medical officer at the British Heart Foundation, noted the long search for effective treatments: "Transthyretin (搜索) amyloidosis causes progressive heart failure (搜索), which can be devastating for patients and their families. We have been searching for effective treatments for a long time and at last they have begun to emerge."
Treatment Landscape and Access
NICE's guidance recommends that the NHS "use the least expensive option of the suitable treatments," including Amvuttra and Vyndaqel (tafamidis), after discussing the advantages and disadvantages of available treatments with patients. Amvuttra has a list price of almost £96,000 ($125,000) per pre-filled syringe but will be supplied to the NHS at a confidential discount.
Phil Davey, country manager at Alnylam Pharmaceuticals (搜索) UK and Ireland, stated: "For decades, people living with this devastating cardiac disease have faced limited treatment options. The team at Alnylam are delighted by the final draft guidance issued by Nice and the recognition of the important role vutrisiran can play in the NHS care of those impacted."
Professor Simon Ray, national clinical director for heart disease at NHS England, highlighted the innovation: "This innovative therapy – which is based on Nobel-prize winning research and can be delivered at home in the longer term – will also offer an alternative to current daily pills for some, and we are delighted that NHS patients will now be able to benefit from it."
The approval represents an important milestone for ATTR-CM (搜索) treatment, though work continues to ensure equitable access across all regions, as the Scottish Medicines Consortium has not yet delivered a decision on vutrisiran for ATTR-CM.